EA202092162A1 - Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака - Google Patents
Антитела против cxcl13 для лечения аутоиммунных заболеваний и ракаInfo
- Publication number
- EA202092162A1 EA202092162A1 EA202092162A EA202092162A EA202092162A1 EA 202092162 A1 EA202092162 A1 EA 202092162A1 EA 202092162 A EA202092162 A EA 202092162A EA 202092162 A EA202092162 A EA 202092162A EA 202092162 A1 EA202092162 A1 EA 202092162A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- autoimmune diseases
- cancer
- antibodies against
- cxcl13
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Предложены антитела или их фрагменты, обладающие специфичностью связывания белка хемокина с (C-X-C-мотивом)-лиганда 13 (CXCL13) человека. В различных примерах антитела или их фрагменты включают области CDR VH и VL, описанные в настоящем документе, или их варианты. Также предложены способы применения указанных антител или их фрагментов для лечения аутоиммунных заболеваний и нарушений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018106158 | 2018-09-18 | ||
PCT/CN2019/106409 WO2020057540A1 (en) | 2018-09-18 | 2019-09-18 | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092162A1 true EA202092162A1 (ru) | 2021-07-01 |
Family
ID=69888374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092162A EA202092162A1 (ru) | 2018-09-18 | 2019-09-18 | Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака |
Country Status (14)
Country | Link |
---|---|
US (2) | US11028164B2 (ru) |
EP (1) | EP3713957A4 (ru) |
JP (1) | JP7098854B2 (ru) |
KR (1) | KR20200106056A (ru) |
CN (1) | CN112469735B (ru) |
AU (2) | AU2019342180B2 (ru) |
BR (1) | BR112021000583A2 (ru) |
CA (1) | CA3098509A1 (ru) |
EA (1) | EA202092162A1 (ru) |
IL (1) | IL281441B2 (ru) |
MX (1) | MX2021002605A (ru) |
SG (1) | SG11202010499UA (ru) |
WO (1) | WO2020057540A1 (ru) |
ZA (1) | ZA202100080B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021202798A1 (en) * | 2020-04-02 | 2021-10-07 | The United States Of America As Represented By The Secretary Of The Navy | Antigen binding proteins to class 5 etec adhesins |
US20230348571A1 (en) * | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
CA3181985A1 (en) | 2020-06-11 | 2021-12-16 | Simone DIGIOVANNI | Use of cxcl13 binding molecules to promote peripheral nerve regeneration |
WO2022133318A2 (en) * | 2020-12-18 | 2022-06-23 | Single Cell Technology, Inc. | Anti-sars corona virus-2 nucleocapsid protein antibodies |
WO2022182562A1 (en) * | 2021-02-23 | 2022-09-01 | BioLegend, Inc. | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS |
CN113234137B (zh) * | 2021-06-21 | 2022-02-25 | 华中农业大学 | 分离自草鱼的CXCL20a蛋白在作为抗菌肽中的应用 |
WO2023196588A2 (en) * | 2022-04-08 | 2023-10-12 | Beam Therapeutics Inc. | Hemoglobin g-makassar binding polypeptides and antibodies and methods of using the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512701B2 (en) * | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
WO2004045526A2 (en) * | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
BRPI0710636A2 (pt) * | 2006-04-21 | 2011-08-23 | Centocor Inc | antagonistas de cxcl 31 e o uso dos mesmos para o tratamento de doenças inflamatórias |
US20080227704A1 (en) * | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US20080199481A1 (en) | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
AU2011295902B2 (en) * | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
US9890213B2 (en) * | 2012-03-02 | 2018-02-13 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
CA2899344C (en) * | 2013-01-31 | 2022-11-08 | Vaccinex, Inc. | Methods for increasing immunoglobulin a levels |
BR112015021964A2 (pt) * | 2013-03-08 | 2017-08-29 | Vaccinex Inc | Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos |
-
2019
- 2019-09-18 EP EP19863616.9A patent/EP3713957A4/en active Pending
- 2019-09-18 EA EA202092162A patent/EA202092162A1/ru unknown
- 2019-09-18 CA CA3098509A patent/CA3098509A1/en not_active Abandoned
- 2019-09-18 BR BR112021000583-8A patent/BR112021000583A2/pt unknown
- 2019-09-18 SG SG11202010499UA patent/SG11202010499UA/en unknown
- 2019-09-18 CN CN201980046759.4A patent/CN112469735B/zh active Active
- 2019-09-18 MX MX2021002605A patent/MX2021002605A/es unknown
- 2019-09-18 AU AU2019342180A patent/AU2019342180B2/en not_active Ceased
- 2019-09-18 WO PCT/CN2019/106409 patent/WO2020057540A1/en unknown
- 2019-09-18 KR KR1020207022061A patent/KR20200106056A/ko not_active Application Discontinuation
- 2019-09-18 US US16/963,130 patent/US11028164B2/en active Active
- 2019-09-18 JP JP2020536028A patent/JP7098854B2/ja active Active
-
2021
- 2021-01-05 ZA ZA2021/00080A patent/ZA202100080B/en unknown
- 2021-03-11 IL IL281441A patent/IL281441B2/en unknown
- 2021-05-20 US US17/326,019 patent/US20210284724A1/en active Pending
- 2021-11-05 AU AU2021261971A patent/AU2021261971A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL281441A (en) | 2021-04-29 |
KR20200106056A (ko) | 2020-09-10 |
ZA202100080B (en) | 2022-06-29 |
AU2021261971A1 (en) | 2021-12-16 |
SG11202010499UA (en) | 2020-11-27 |
US20210284724A1 (en) | 2021-09-16 |
JP7098854B2 (ja) | 2022-07-12 |
CA3098509A1 (en) | 2020-03-26 |
AU2019342180B2 (en) | 2021-08-05 |
BR112021000583A2 (pt) | 2021-04-06 |
WO2020057540A1 (en) | 2020-03-26 |
CN112469735B (zh) | 2022-11-08 |
CN112469735A (zh) | 2021-03-09 |
JP2021513324A (ja) | 2021-05-27 |
EP3713957A4 (en) | 2021-08-18 |
US20200399360A1 (en) | 2020-12-24 |
AU2019342180A1 (en) | 2020-07-16 |
EP3713957A1 (en) | 2020-09-30 |
WO2020057540A8 (en) | 2020-07-23 |
US11028164B2 (en) | 2021-06-08 |
IL281441B2 (en) | 2023-02-01 |
IL281441B (en) | 2022-10-01 |
MX2021002605A (es) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092162A1 (ru) | Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака | |
EA202190378A1 (ru) | Антитела против ifnar1 для лечения аутоиммунных заболеваний | |
EA201992765A1 (ru) | Белки на основе антител с привитым цитокином и способы их применения в лечении рака | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
WO2019157366A8 (en) | Antibody variable domains targeting the nkg2d receptor | |
CR20220408A (es) | ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198) | |
MX2018016404A (es) | Anticuerpos de union a cd3. | |
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
NZ756678A (en) | Anti-lag-3 antibodies and uses thereof | |
MX2016011414A (es) | Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos. | |
UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
WO2019204462A3 (en) | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
MX2022005866A (es) | Anticuerpos biparatopicos frente a cd73. | |
WO2020089396A3 (en) | Composition and methods of treating inflammatory and autoimmune diseases | |
EA202092459A1 (ru) | Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают | |
MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
EA202190094A1 (ru) | Антитела против cd40 для применения в лечении аутоиммунного заболевания | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения |